HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLOUDBREAK-B

1.190

0.000

Volume:- -

Turnover:- -

Market Cap:1.10B

PE:-11.55

High:1.190

Open:1.190

Low:1.190

Close:1.190

52wk High:9.580

52wk Low:0.900

Shares:925.00M

HK Float Shares:925.00M

Volume Ratio:0.37

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.103

ROE:--

ROA:-190.68%

PB:3.34

PE(LYR):-11.55

PS:521.78

Loading ...

Overview Company News Filings

Cloudbreak Pharma Names Tsang Ngo Yin Company Secretary, Authorized Representative After Fung Nga Fong Exit

Cloudbreak-B Initiates Discounted ATM Offering Amid Clinical Milestones, Yet Losses and Cash Burn Persist, Shares Down Over 80% Since IPO

Cloudbreak Pharma Files HKEX Next-day Disclosure Return, Lifts Share Capital by 22,848,000 Shares

Cloudbreak Pharma Adopts AGM Resolutions by Shareholder Vote

Cloudbreak Pharma survey shows pinguecula patients report high burden, strong interest in prescription treatment

Cloudbreak-B Announces Proposed Issuance of Subscription Shares to Abraham Dominguez Cinta

CLOUDBREAK-B Announces Proposed Share Subscription to Abraham Dominguez Cinta

Cloudbreak Pharma to Raise up to US$15.00 Million via Share Subscription with ARC Group

Bulletin Express

Cloudbreak Pharma - Enters Share Subscription Agreement With ARC Group International for up to $15 Mln

THOMSON REUTERS

Cloudbreak Pharma signs share subscription deal for up to US$15 million with ARC Group unit

CLOUDBREAK-B Issues 5.712 Million Shares Under Equity Incentive Plan

Cloudbreak Pharma - Topline 12-Month Efficacy Data for Cbt-1 Phase 3 Trial Expected in Q3 2026

THOMSON REUTERS

Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of Cbt-001 as a Potential Treatment for Pterygium

THOMSON REUTERS

Cloudbreak-B Completes Final 12-Month Endpoint Visit for CBT-001

Cloudbreak Pharma Submits IND Application For Cbt-358 To FDA

Cloudbreak Pharma Issues AGM Notice; Proposes Director Re-elections, 20% Share Issuance Mandate and 10% Buyback Limit

Bulletin Express

Cloudbreak Pharma Files FDA IND for Dry-Eye Candidate CBT-358

Bulletin Express

Cloudbreak Pharma Revises Allocation of HK$524.60 Million IPO Proceeds, Redirects HK$103.60 Million Toward Expanded R&D and Working Capital

Bulletin Express

CLOUDBREAK-B (02592) Submits Investigational New Drug Application for CBT-358

Cloudbreak Pharma reallocates HK$103.6 million IPO proceeds to expand dry-eye R&D programs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/02592/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02592","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","market":"HK","secType":"STK","nameCN":"CLOUDBREAK-B","latestPrice":1.19,"timestamp":1789089613343,"preClose":1.19,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":925000000,"shares":925000000,"eps":-0.103023,"marketStatus":"Halted","change":0,"latestTime":"09-11 09:20:13","open":1.19,"high":1.19,"low":1.19,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.024,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"listingDate":1751472000000,"exchange":"SEHK","adjPreClose":1.19,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":0.369999998816,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","floatShares":925000000,"roa":"-190.68%","roe":"--","lyrEps":-0.103023,"volumeRatio":0.369999998816,"shares":925000000,"dividePrice":0,"high":1.19,"amplitude":0,"preClose":1.19,"low":1.19,"week52Low":0.9,"pbRate":"3.34","psRate":"521.78","week52High":9.58,"institutionHeld":0,"latestPrice":1.19,"eps":-0.103023,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.024,"open":1.19,"prevYearClose":5.2,"prevWeekClose":1.19,"prevMonthClose":1.145,"prevQuarterClose":1.56,"fiveDayClose":1.18,"twentyDayClose":1.175,"sixtyDayClose":1.21},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02592\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-30","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null},{"date":"2025-08-29","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02592\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02592\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02592\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02592","date":"2026-09-11","current":-1.162109,"percent":0.97619,"low":-24.505522,"twenty":-11.839754,"median":-5.586446,"eighty":-2.054785,"high":-1.021022,"avg":-6.532259,"sd":4.944909,"marketCap":1005033411},"quantilePoints":[{"date":"2025-07-04","current":-6.317277,"twenty":-6.610502,"median":-6.500542,"eighty":-6.390583,"marketCap":4915912241},{"date":"2025-07-11","current":-6.166376,"twenty":-6.470405,"median":-6.317277,"eighty":-6.263403,"marketCap":4798467239},{"date":"2025-07-18","current":-6.350904,"twenty":-6.498689,"median":-6.350281,"eighty":-6.263403,"marketCap":4941079027},{"date":"2025-07-25","current":-6.080141,"twenty":-6.48004,"median":-6.306537,"eighty":-6.134066,"marketCap":4731355809},{"date":"2025-08-01","current":-5.497985,"twenty":-6.418895,"median":-6.177156,"eighty":-6.011186,"marketCap":4278353657},{"date":"2025-08-08","current":-5.49809,"twenty":-6.350655,"median":-6.13405,"eighty":-5.65539,"marketCap":4278353657},{"date":"2025-08-15","current":-5.725306,"twenty":-6.343182,"median":-6.058573,"eighty":-5.554248,"marketCap":4446132232},{"date":"2025-08-22","current":-5.53457,"twenty":-6.315129,"median":-6.004685,"eighty":-5.554248,"marketCap":4286742586},{"date":"2025-08-29","current":-5.503941,"twenty":-6.295753,"median":-5.870846,"eighty":-5.538055,"marketCap":4253186871},{"date":"2025-09-05","current":-5.413205,"twenty":-6.239682,"median":-5.742284,"eighty":-5.49926,"marketCap":4186075441},{"date":"2025-09-12","current":-12.640894,"twenty":-6.350655,"median":-5.870846,"eighty":-5.508123,"marketCap":4118964011},{"date":"2025-09-19","current":-12.711577,"twenty":-6.612702,"median":-6.004685,"eighty":-5.525012,"marketCap":4135741868},{"date":"2025-09-26","current":-11.804503,"twenty":-12.358821,"median":-6.058573,"eighty":-5.527436,"marketCap":3842129362},{"date":"2025-10-03","current":-6.439136,"twenty":-12.191113,"median":-6.134046,"eighty":-5.53457,"marketCap":2096453591},{"date":"2025-10-10","current":-5.988337,"twenty":-11.881825,"median":-6.134089,"eighty":-5.548508,"marketCap":1949083838},{"date":"2025-10-17","current":-12.3346,"twenty":-12.21981,"median":-6.187936,"eighty":-5.561014,"marketCap":4009907937},{"date":"2025-10-24","current":-11.844495,"twenty":-12.25273,"median":-6.279578,"eighty":-5.580054,"marketCap":3850518291},{"date":"2025-10-31","current":-12.15705,"twenty":-12.335851,"median":-6.333467,"eighty":-5.585568,"marketCap":3951185436},{"date":"2025-11-07","current":-11.838569,"twenty":-12.273198,"median":-6.424535,"eighty":-5.601607,"marketCap":3850518291},{"date":"2025-11-14","current":-11.510378,"twenty":-12.207573,"median":-6.465107,"eighty":-5.621104,"marketCap":3741462218},{"date":"2025-11-21","current":-12.23865,"twenty":-12.234818,"median":-6.500592,"eighty":-5.630174,"marketCap":3984741151},{"date":"2025-11-28","current":-21.343443,"twenty":-12.412307,"median":-6.613869,"eighty":-5.677994,"marketCap":6946032996},{"date":"2025-12-05","current":-20.614529,"twenty":-12.626633,"median":-6.790202,"eighty":-5.718633,"marketCap":6711142992},{"date":"2025-12-12","current":-17.961539,"twenty":-12.716498,"median":-11.142834,"eighty":-5.735493,"marketCap":5847083331},{"date":"2025-12-19","current":-14.819321,"twenty":-12.837409,"median":-11.27102,"eighty":-5.75741,"marketCap":4823634025},{"date":"2025-12-24","current":-14.055026,"twenty":-12.984934,"median":-11.600706,"eighty":-5.767869,"marketCap":4571966163},{"date":"2026-01-02","current":-11.620216,"twenty":-12.995771,"median":-11.729724,"eighty":-5.769371,"marketCap":3783406861},{"date":"2026-01-09","current":-7.540769,"twenty":-12.961935,"median":-11.510378,"eighty":-5.972321,"marketCap":2457956120},{"date":"2026-01-16","current":-8.049692,"twenty":-12.941587,"median":-11.169175,"eighty":-5.988337,"marketCap":2625734695},{"date":"2026-01-23","current":-6.609576,"twenty":-12.863288,"median":-10.620058,"eighty":-5.996682,"marketCap":2155954686},{"date":"2026-01-30","current":-6.294491,"twenty":-12.820156,"median":-9.452561,"eighty":-6.004685,"marketCap":2055287541},{"date":"2026-02-06","current":-5.800172,"twenty":-12.797534,"median":-8.075865,"eighty":-6.004685,"marketCap":1895897895},{"date":"2026-02-13","current":-5.772062,"twenty":-12.788929,"median":-7.957902,"eighty":-5.976779,"marketCap":1887508966},{"date":"2026-02-20","current":-5.722622,"twenty":-12.762909,"median":-7.89408,"eighty":-5.899654,"marketCap":1870731109},{"date":"2026-02-27","current":-5.716309,"twenty":-12.718958,"median":-7.540769,"eighty":-5.819712,"marketCap":1870731109},{"date":"2026-03-06","current":-5.592845,"twenty":-12.7039,"median":-6.802294,"eighty":-5.77076,"marketCap":1828786465},{"date":"2026-03-13","current":-5.252211,"twenty":-12.674344,"median":-6.763399,"eighty":-5.752368,"marketCap":1719730391},{"date":"2026-03-20","current":-4.787506,"twenty":-12.644727,"median":-6.625153,"eighty":-5.711698,"marketCap":1568729674},{"date":"2026-03-27","current":-4.279308,"twenty":-12.631386,"median":-6.530805,"eighty":-5.600393,"marketCap":1400951099},{"date":"2026-04-02","current":-4.3756,"twenty":-12.611231,"median":-6.512878,"eighty":-5.567465,"marketCap":1434506814},{"date":"2026-04-10","current":-4.248889,"twenty":-12.593551,"median":-6.499576,"eighty":-5.532786,"marketCap":1392562170},{"date":"2026-04-17","current":-3.434267,"twenty":-12.529717,"median":-6.439136,"eighty":-5.502771,"marketCap":1124116451},{"date":"2026-04-24","current":-3.028108,"twenty":-12.499065,"median":-6.412742,"eighty":-5.465751,"marketCap":1604675194},{"date":"2026-04-30","current":-2.35827,"twenty":-12.455796,"median":-6.350281,"eighty":-5.436669,"marketCap":1249957520},{"date":"2026-05-08","current":-2.422963,"twenty":-12.412307,"median":-6.306537,"eighty":-5.348441,"marketCap":1283740155},{"date":"2026-05-15","current":-2.215232,"twenty":-12.362936,"median":-6.237324,"eighty":-5.224545,"marketCap":1173946589},{"date":"2026-05-22","current":-2.103037,"twenty":-12.335851,"median":-6.187936,"eighty":-5.079251,"marketCap":1114826977},{"date":"2026-05-29","current":-2.055189,"twenty":-12.29622,"median":-6.159956,"eighty":-4.693687,"marketCap":1089490000},{"date":"2026-06-05","current":-1.943602,"twenty":-12.236095,"median":-6.134636,"eighty":-4.452767,"marketCap":1030370388},{"date":"2026-06-12","current":-2.070618,"twenty":-12.215803,"median":-6.134042,"eighty":-4.302022,"marketCap":1097935659},{"date":"2026-06-18","current":-1.863414,"twenty":-12.1843,"median":-6.080141,"eighty":-4.208883,"marketCap":988142093},{"date":"2026-06-26","current":-1.607919,"twenty":-12.150518,"median":-6.004708,"eighty":-3.379693,"marketCap":853011550},{"date":"2026-07-03","current":-2.053171,"twenty":-12.124388,"median":-5.992509,"eighty":-2.739542,"marketCap":1089490000},{"date":"2026-07-10","current":-2.134398,"twenty":-12.109822,"median":-5.972321,"eighty":-2.532616,"marketCap":1131718295},{"date":"2026-07-17","current":-2.101828,"twenty":-11.973906,"median":-5.886479,"eighty":-2.422963,"marketCap":1114826977},{"date":"2026-07-24","current":-2.069578,"twenty":-11.968515,"median":-5.84391,"eighty":-2.309668,"marketCap":1097935659},{"date":"2026-07-31","current":-1.862057,"twenty":-11.947093,"median":-5.798666,"eighty":-2.247923,"marketCap":988142093},{"date":"2026-08-07","current":-1.925288,"twenty":-11.910048,"median":-5.770977,"eighty":-2.212119,"marketCap":1021924729},{"date":"2026-08-14","current":-1.869116,"twenty":-11.882099,"median":-5.767494,"eighty":-2.165101,"marketCap":992364923},{"date":"2026-08-21","current":-1.909914,"twenty":-11.871403,"median":-5.723964,"eighty":-2.134253,"marketCap":1013479070},{"date":"2026-08-28","current":-1.839188,"twenty":-11.868929,"median":-5.708624,"eighty":-2.114609,"marketCap":975473605},{"date":"2026-09-04","current":-1.052314,"twenty":-11.849329,"median":-5.61954,"eighty":-2.086117,"marketCap":996587752},{"date":"2026-09-11","current":-1.061097,"twenty":-11.839754,"median":-5.586446,"eighty":-2.054785,"marketCap":1005033411}],"updateTime":1789338822589},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02592\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2652402188","title":"Cloudbreak Pharma Names Tsang Ngo Yin Company Secretary, Authorized Representative After Fung Nga Fong Exit","url":"https://stock-news.laohu8.com/highlight/detail?id=2652402188","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652402188?lang=en_us&edition=fundamental","pubTime":"2026-07-17 18:30","pubTimestamp":1784284228,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma names Tsang Ngo Yin company secretary, authorized representative after Fung Nga Fong exitCloudbreak Pharma named Tsang Ngo Yin as company secretary, effective July 17, 2026, replacing Fung Nga Fong, who resigned.Tsang brings 20+ years in regulatory compliance, corporate finance, company secretarial work, internal control, auditing, financial management.Tsang holds a BBA from Simon Fraser University, an LLB from Tsinghua University, an LLM from the University of Wolverhampton.She is a member of the AICPA, the HKICPA, currently serves as company secretary of HG Semiconductor .Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nNDL24TNYp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1163","02592","06908","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169608073","title":"Cloudbreak-B Initiates Discounted ATM Offering Amid Clinical Milestones, Yet Losses and Cash Burn Persist, Shares Down Over 80% Since IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1169608073","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169608073?lang=en_us&edition=fundamental","pubTime":"2026-07-02 20:51","pubTimestamp":1782996676,"startTime":"0","endTime":"0","summary":"Since its listing on the Hong Kong Stock Exchange in July 2025, Cloudbreak-B (02592.HK), a company once hailed as a star in innovative ophthalmic drugs, has seen disappointing stock performance....","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159399","IPOS","BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647536666","title":"Cloudbreak Pharma Files HKEX Next-day Disclosure Return, Lifts Share Capital by 22,848,000 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2647536666","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647536666?lang=en_us&edition=fundamental","pubTime":"2026-06-30 16:42","pubTimestamp":1782808935,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma files HKEX next-day disclosure return, lifts share capital by 22,848,000 sharesCloudbreak Pharma filed a next-day disclosure return on June 30, 2026 covering an increase in issued shares.Issued 22,848,000 new ordinary shares under its 2023 Equity Incentive Scheme at HKD 0 per share.Issued shares rose 2.66% to 880,467,081 from 857,619,081; treasury shares stayed at 0.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDLbnJ13Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646089350","title":"Cloudbreak Pharma Adopts AGM Resolutions by Shareholder Vote","url":"https://stock-news.laohu8.com/highlight/detail?id=2646089350","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646089350?lang=en_us&edition=fundamental","pubTime":"2026-06-26 21:27","pubTimestamp":1782480476,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma adopts AGM resolutions by shareholder voteShareholders met on June 26, 2026.Adopted the audited financial statements for the year ended Dec. 31, 2025, alongside the directors’ and au","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL191XKK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645024681","title":"Cloudbreak Pharma survey shows pinguecula patients report high burden, strong interest in prescription treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2645024681","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645024681?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:00","pubTimestamp":1782129658,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma released results from an April–May 2026 U.S. patient survey on pinguecula; full findings are slated for a peer-reviewed journal.Survey indicates the condition is widely viewed as bothersome, with symptoms reported to disrupt daily comfort and quality of life.Responses suggest meaningful demand for a prescription treatment despite no FDA-approved drug specifically for pinguecula.Management positioned the survey as commercial and clinical support for CBT-004, following earlier Phase 2 results it described as encouraging.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLb5h4H7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157202204","title":"Cloudbreak-B Announces Proposed Issuance of Subscription Shares to Abraham Dominguez Cinta","url":"https://stock-news.laohu8.com/highlight/detail?id=1157202204","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157202204?lang=en_us&edition=fundamental","pubTime":"2026-06-22 08:30","pubTimestamp":1782088252,"startTime":"0","endTime":"0","summary":" CLOUDBREAK-B (ASX: 02592) has announced that on June 18, 2026, following trading hours, the company entered into a share subscription agreement with investor ARC Group International Limited.Under...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156269895","title":"CLOUDBREAK-B Announces Proposed Share Subscription to Abraham Dominguez Cinta","url":"https://stock-news.laohu8.com/highlight/detail?id=1156269895","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156269895?lang=en_us&edition=fundamental","pubTime":"2026-06-18 23:08","pubTimestamp":1781795290,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) has disclosed an agreement to issue new shares to an investor.On June 18, 2026, following market close, the company entered into a share subscription pact with investor ARC Group...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193630343","title":"Cloudbreak Pharma to Raise up to US$15.00 Million via Share Subscription with ARC Group","url":"https://stock-news.laohu8.com/highlight/detail?id=1193630343","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193630343?lang=en_us&edition=fundamental","pubTime":"2026-06-18 23:05","pubTimestamp":1781795128,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. (CLOUDBREAK-B, 02592) has signed a Share Subscription Agreement with ARC Group International Ltd. that entitles the investor to subscribe for new shares worth up to US$15.00...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644084213","title":"Cloudbreak Pharma - Enters Share Subscription Agreement With ARC Group International for up to $15 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2644084213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644084213?lang=en_us&edition=fundamental","pubTime":"2026-06-18 22:51","pubTimestamp":1781794276,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nFWN42Q0TG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644084210","title":"Cloudbreak Pharma signs share subscription deal for up to US$15 million with ARC Group unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2644084210","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644084210?lang=en_us&edition=fundamental","pubTime":"2026-06-18 22:51","pubTimestamp":1781794269,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma entered a share subscription deal for up to USD 15 million of new shares with ARC Group International.Issuance can occur in multiple drawdowns over 12 months, capped at 167,778,574 shares under an existing general mandate.Pricing set at 93% of average closing bid over a 15-day pricing period, subject to a floor of HKD 1.03.Maximum net proceeds estimated at USD 14.51 million, earmarked for R&D, PRC bank loan repayment, working capital.Commitment fee set at USD 0.3 million in cash, with 60% payable within five business days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong K","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL3Ch96D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113708786","title":"CLOUDBREAK-B Issues 5.712 Million Shares Under Equity Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1113708786","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113708786?lang=en_us&edition=fundamental","pubTime":"2026-06-09 16:38","pubTimestamp":1780994299,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) has announced the allotment and issuance of 5.712 million shares.The issuance was completed on June 9, 2026, in accordance with the company's 2023 equity incentive plan.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641453167","title":"Cloudbreak Pharma - Topline 12-Month Efficacy Data for Cbt-1 Phase 3 Trial Expected in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2641453167","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641453167?lang=en_us&edition=fundamental","pubTime":"2026-06-05 05:00","pubTimestamp":1780606800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nTUA73ZCCQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641167454","title":"Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of Cbt-001 as a Potential Treatment for Pterygium","url":"https://stock-news.laohu8.com/highlight/detail?id=2641167454","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641167454?lang=en_us&edition=fundamental","pubTime":"2026-06-05 05:00","pubTimestamp":1780606800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nTUA73ZCCQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112548739","title":"Cloudbreak-B Completes Final 12-Month Endpoint Visit for CBT-001","url":"https://stock-news.laohu8.com/highlight/detail?id=1112548739","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112548739?lang=en_us&edition=fundamental","pubTime":"2026-06-04 18:52","pubTimestamp":1780570358,"startTime":"0","endTime":"0","summary":"The final patient has completed a 12-month visit, during which the primary efficacy endpoints of CBT-001—the degree of pterygium lesion reduction and ocular discomfort symptom scores—were evaluated...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","CBT","BK1161","BK4090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637343690","title":"Cloudbreak Pharma Submits IND Application For Cbt-358 To FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2637343690","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637343690?lang=en_us&edition=fundamental","pubTime":"2026-05-22 23:26","pubTimestamp":1779463570,"startTime":"0","endTime":"0","summary":"May 22 (Reuters) - Cloudbreak Pharma Inc <2592.HK>::*SUBMITS IND APPLICATION FOR CBT-358 TO FDA*Further company coverage: 2592.HK* ((Reuters.Briefs@thomsonreuters.com;))  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 22-MAY-202615:07:00.113 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nRSD9hDhvr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117476828","title":"Cloudbreak Pharma Issues AGM Notice; Proposes Director Re-elections, 20% Share Issuance Mandate and 10% Buyback Limit","url":"https://stock-news.laohu8.com/highlight/detail?id=1117476828","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117476828?lang=en_us&edition=fundamental","pubTime":"2026-05-22 23:23","pubTimestamp":1779463411,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. (CLOUDBREAK-B) has released its notice of Annual General Meeting, scheduling the session for 26 June 2026 at 09:30 a.m. Hong Kong Time (25 June 2026 at 06:30 p.m. PDT) at 8921...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196922661","title":"Cloudbreak Pharma Files FDA IND for Dry-Eye Candidate CBT-358","url":"https://stock-news.laohu8.com/highlight/detail?id=1196922661","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196922661?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:43","pubTimestamp":1779461021,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. (Cloudbreak) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration on 21 May 2026 for CBT-358, according to a voluntary...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120533332","title":"Cloudbreak Pharma Revises Allocation of HK$524.60 Million IPO Proceeds, Redirects HK$103.60 Million Toward Expanded R&D and Working Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=1120533332","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120533332?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:43","pubTimestamp":1779460989,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. announced a material re-allocation of the HK$524.60 million net proceeds raised in its June 2025 global offering, shifting HK$103.60 million from the originally earmarked Phase...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100019197","title":"CLOUDBREAK-B (02592) Submits Investigational New Drug Application for CBT-358","url":"https://stock-news.laohu8.com/highlight/detail?id=1100019197","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100019197?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:40","pubTimestamp":1779460828,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that on May 21, 2026, the group submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for CBT-358. CBT-358 is the most...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBT","BK4090","02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637348801","title":"Cloudbreak Pharma reallocates HK$103.6 million IPO proceeds to expand dry-eye R&D programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2637348801","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637348801?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:37","pubTimestamp":1779460672,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma outlined a revised funding plan for the HK$524.6 million in net IPO proceeds, shifting HK$103.6 million away from CBT-009 following the decision to withdraw its current China IND application for a possible phase 3 trial.Reallocated funds target faster clinical and regulatory work on CBT-001 and CBT-004, accelerated development of SFA+ pipeline assets including CBT-358 and CBT-277, and higher general corporate funding.Under the revised plan, total allocations rise to HK$359.2 million for CBT-001 and CBT-004 programs, HK$84.1 million for CBT-009, CBT-358 and CBT-277, HK$28.8 million for manufacturing and commercialization, and HK$52.5 million for working capital.Unutilized proceeds stood at HK$312.6 million, with spending to be governed by tighter board-level budgeting and authorization controls.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL7HxKHn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":70,"code":"91000000","status":"200"}]}}